A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY AT RISK OF PROGRESSIVE LOSS OF RENAL FUNCTION (THE ALIGN STUDY)
- Registry ID
- CEXV811A12301 (CHK01-01)
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- CHINOOK THERAPEUTICS U.S., INC.
- Start date
- 2022-06-14
- Last update
- 2021-03-01
Conditions
Related clinical trials
- A MULTICENTER OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ZIGAKIBART IN ADULTS WITH PRIMARY IGA NEPHROPATHY
- A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE EFFICACY AND SAFETY OF MEZAGITAMAB (TAK-079) IN STUDY PARTICIPANTS WITH PRIMARY IGA NEPHROPATHY IN COMBINATION WITH STABLE BACKGROUND THERAPY
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF FELZARTAMAB
IN ADULTS WITH IGA NEPHROPATHY
- A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF SEFAXERSEN, AN ANTISENSE INHIBITOR OF
COMPLEMENT FACTOR B, IN PATIENTS WITH PRIMARY IGA NEPHROPATHY AT HIGH RISK OF PROGRESSION
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN
ADULTS WITH IGA NEPHROPATHY (THE BEYOND STUDY)
- A PHASE IIB RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATACICEPT IN SUBJECTS WITH IGA NEPHROPATHY (IGAN)
View on source registry